CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C Academic Article uri icon

Overview

MeSH Major

  • Biomarkers
  • Chemokine CXCL10
  • Chemokine CXCL9
  • Hepatitis C, Chronic
  • Liver Cirrhosis

abstract

  • CXCL9 (monokine induced by IFN γ [Mig]) and CXCL10 (interferon [IFN] γ-inducible protein 10 [IP-10]) have been associated with hepatic fibrosis in predominantly white hepatitis C virus (HCV)-infected patients. We investigated their potential as noninvasive markers of hepatic fibrosis and fibrosis progression in African-American patients. Peripheral chemokine levels were measured in 115 HCV-infected patients within 4 months of liver biopsy; patients underwent a second biopsy after 3-5 years. CXCL10 levels appeared to be higher in patients with advanced fibrosis on the contemporaneous biopsy and were significantly higher in patients with advanced fibrosis compared with those with minimal fibrosis on the later biopsy (P = .0045). Therefore, CXCL10 has potential as a marker of fibrosis progression in African-American HCV-infected patients.

publication date

  • September 15, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3156920

Digital Object Identifier (DOI)

  • 10.1093/infdis/jir424

PubMed ID

  • 21849280

Additional Document Info

start page

  • 832

end page

  • 6

volume

  • 204

number

  • 6